1294. Longitudinal Global Analysis for Enterobacteriaceae; a Report from the TEST Program 2004-2012
Session: Poster Abstract Session: Below the Diaphragm
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • IDSA 1294.pdf (201.6 kB)
  • Background: The Tigecycline Evaluation Surveillance Trial (TEST) is a global longitudinal surveillance study that has been monitoring the activity of a number of antimicrobial agents against both gram-negative and gram-positive organisms since 2004. This study reports the long term analysis of these data for Enterobacteriaceae from 2004 through 2012.

    Methods: A total of 110,615 Enterobacteriaceae isolates from 2,330 cumulative sites and 66 countries in Europe, North America, Asia, Latin America, Africa, Middle East, and South Pacific was evaluated. MICs were determined using common broth microdilution panels and interpretive criteria according to CLSI or FDA guidelines. The Cochran-Armitage Trend Test was used to evaluate significance over time. 

    Results:

    % Susceptible is provided by year for each antimicrobial:

    % Susceptible by Year and Cumulative Years

    Year

    2004

    2005

    2006

    2007

    2008

    2009

    2010

    2011

    2012

    2004-
    2012

    P-

    value*

    n's

    8575

    9276

    12951

    16789

    15615

    7617

    15461

    12112

    12219

    110615

    Amikacin

    99

    98

    97

    97

    95

    95

    97

    97

    97

    97

    <0.0001

    AmoxClav

    48

    48

    45

    45

    40

    40

    41

    41

    45

    43

    <0.0001

    Cefepime

    95

    93

    91

    90

    86

    87

    87

    86

    88

    89

    <0.0001

    Ceftriaxone

    81

    79

    75

    75

    68

    68

    68

    69

    73

    72

    <0.0001

    Levofloxacin

    87

    84

    81

    81

    75

    76

    77

    75

    80

    79

    <0.0001

    Meropenem

    na

    na

    97

    97

    97

    95

    98

    97

    97

    97

    0.0008

    Minocycline

    85

    85

    82

    79

    67

    64

    63

    63

    83

    74

    <0.0001

    PipTazo

    90

    88

    86

    86

    80

    80

    81

    81

    86

    84

    <0.0001

    Tigecycline

    96

    97

    97

    98

    97

    96

    97

    97

    97

    97

    0.073

    Conclusion: Tigecycline demonstrated no significant decrease in % susceptible (p=0.073) against all Enterobacteriaceae since its initial pre-marketing values in 2004.  All other study drugs demonstrated significant decreases over the period of this study (p-values 0.0008 to <0.0001) although amikacin, meropenem, and tigecycline had equivalent in vitro activity in the last study year inhibiting ≥97% of all Enterobacteriaceae at their respective breakpoints. 

    Samuel Bouchillon, MD1, Douglas Biedenbach, BS2, Meredith Hackel, PhD1, Brian Johnson, BS3, Stephen Hawser, PhD4 and Heidi Leister-Tebbe, BS5, (1)Ihma, Inc., Schaumburg, IL, (2)Ihma Inc., Schaumburg, IL, (3)IHMA, Inc., Schaumburg, IL, (4)Ihma Europe SÓrl, Epalinges, Switzerland, (5)Pfizer Inc., Collegeville, PA

    Disclosures:

    S. Bouchillon, None

    D. Biedenbach, None

    M. Hackel, None

    B. Johnson, None

    S. Hawser, None

    H. Leister-Tebbe, Pfizer Inc.: Employee, Salary

    See more of: Below the Diaphragm
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.